Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial Fibrillation in the Barbanza Area Study)

International Journal of Cardiology

Volumn 153, Issue 1, 2011, Pages 68-73

  García Castelo, Alberto ^a   García Seara, Javier ^a   Otero Raviña, Fernando ^a   Lado, Manuel ^b   Vizcaya, Andrés ^c   Vidal, Juan M ^d   Lafuente, Ramón ^e   Bouza, David ^f   Lear, Pamela V ^a   González Juanatey, José R ^a  

^a University Hospital of Santiago de Compostela   (Spain)

^b Primary Care Unit of Ribeira   (Spain)

^c Primary Care Unit of Cabana de Bergantiños   (Spain)

^d Primary Care Unit of Touro   (Spain)

^e Primary Care Unit of Outes   (Spain)

^f Primary Care Unit of Ventorrillo   (Spain)

Author keywords

Atrial fibrillation; Mortality; Primary care

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEALTH SERVICE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OVERALL SURVIVAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SPAIN; SYSTOLIC DYSFUNCTION;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RESIDENCE CHARACTERISTICS; SPAIN;

EID: 81055144288     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.08.042     Document Type: Article

References (57)

1. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. The Anticoagulation and Risk Factors Atrial Fibrillation (ATRIA) study JAMA 285 2001 2370 2375
2. P.A. Wolf, E.J. Benajamin, and A.J. Belanguer Secular trends in prevalence of atrial fibrillation: the Framingham study Am Heart J 131 1996 790 795
3. Y. Miyasaka, M.E. Barnes, and B.J. Gersh Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125
4. A.D. Krahn, J. Manfreda, R. Tate, F. Mathewson, and T. Cuddy Natural history of atrial fibrillation; incidence, risk factors and prognosis in the Manitoba follow-up study Am J Med 98 1995 May 476 484
5. W.B. Kannel, P.A. Wolf, E.J. Benjamin, and D. Levy Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates Am J Cardiol 82 1998 2N 9N
6. W.M. Feinberg, J.L. Blackshear, and A. Laupasis Prevalence, age distribution and gender in patients with atrial fibrillation: analysis and implications Arch Intern Med 155 1995 469 473
7. P.T. Onundarson, G. Thorgeirsson, E. Jonmundsson, N. Sigfusson, and T. Hardarson Chronic atrial fibrillation-epidemiologic features and 14 year follow-up: a case control study Eur Heart J 8 1987 521 527
8. S. Stewart, N. Murphy, A. Walker, A. McGuire, and J.J.V. McMurray Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK Heart 90 2004 286 292
9. N.F. Murphy, C.R. Simpson, and P.S. Jhund A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland Heart 93 2007 606 612
10. Ceresne Lance, and Upshur Ross Atrial fibrillation in primary care practice: prevalence and management BMC Fam Pract 3 2002 11
11. F.N. Brand, R.D. Abbott, W.B. Kannel, and P.A. Wolf Characteristics and prognosis of lone atrial fibrillation. 30-Year follow-up in the Framingham study JAMA 254 1985 3449 3453
12. S.L. Kopecky, B.J. Gersh, and M.D. McGoon The natural history of lone atrial fibrillation. A population-based study over three decades N Engl J Med 317 1987 669 674
13. S. Levy, M. Mareek, and P. Coumel Characterization of different subsets of atrial fibrillation in general practice in France; the ALFA study: the College of French cardiologists Circulation 99 1999 3028 3035
14. B. Schnabel Renate, M. Sullivan Lisa, Levy Daniel, J. Pencina Michael, M. Massaro Joseph, and B. D'Agostino Ralph Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study Lancet 373 2009 739 745
15. E.J. Benjamin, D. Levy, S.M. Vaziri, R.B. D' Agostino, A.J. Belanger, and P.A. Wolf Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 271 1994 840 844
16. J.Y. Le Heuzey, G. Breithardt, and J. Camm The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation Am J Cardiol 105 5 2010 687 693
17. A. Cameron, M.J. Schwartz, R.A. Fronmal, and A.S. Kosinski Prevalence and significance of atrial fibrillation in coronary artery disease (CASS registry) Am J Cardiol 61 1988 714 717
18. W.B. Kannel, R.D. Abbott, D.D. Savage, and P.M. McNamara Coronary heart disease and atrial fibrillation: the Framingham Study Am Heart J 106 1983 389 396
19. B.S. Crenshaw, S.R. Ward, and C.B. Grangcr For the GUSTO-1 trial investigators. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-1 experience J Am Coll Cardiol 30 1997 406 413
20. S. Behar, D. Tanne, and M. Zion For the SPRINT study group. Incidence and prognostic significance of chronic atrial fibrillation among 5839 consecutive patients with acute myocardial infarction Am J Cardiol 70 1992 816 818
21. Stroke Prevention in Atrial Fibrillation Investigators Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk Ann Intern Med 116 1992 1 5
22. Stroke Prevention in Atrial Fibrillation Investigators Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk Ann Intern Med 116 1992 6 12
23. T.J. Wang, J.M. Massaro, and D. Levy A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study JAMA 290 2003 1049 1056
24. H.-J. Lin, P.A. Wolf, and E.J. Benjamin Newly diagnosed atrial fibrillation and acute: stroke. The Framingham Study Stroke 26 1995 1527 1530
25. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
26. M. Ruiz, E. Romo, and M. Zapata Oral anticoagulation in patients aged 75 years or older with chronic non valvular atrial fibrillation: effectiveness and safety in daily clinical practice Heart 91 2005 1225 1226
27. Stroke Prevention in Atrial Fibrillation Investigators Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study J Stroke Cerebrovasc Dis 5 1995 147 157
28. P. Petersen, G. Boysen, J. Godtfredsen, E.D. Andersen, and B. Andersen Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study Lancet 1 1989 175 179
29. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation N Engl J Med 323 1990 1505 1511
30. S.J. Connolly, A. Laupacis, M. Gent, R.S. Roberts, J.A. Cairns, and C. Joyner Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J Am Coll Cardiol 18 1991 349 355
31. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet 343 1994 687 691
32. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial Lancet 348 1996 633 638
33. T.J. Wang, M. Larson, and D. Levy Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study Circulation 107 2003 2920 2925
34. P.E. Carson, G.R. Johnson, and W.B. Dunkman For the V-HEFT VA cooperative studies group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HEFT studies Circulation 87 1993 VI 102 VI 110
35. Maximo Rivera-Ayerza, Wilma Scholte op Reimer, and Mattie Lenzen New onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey Eur Heart J 29 2008 1618 1624
36. M. Meiltz Am Zimmermann, P. Urban, and A. Block Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world Europace 10 2008 674 680
37. S.H. Hohnloser, K.H. Kuck, and J. Lilienthal Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial Lancet 356 2000 1789 1794
38. I.C. Van Gelder, A. Waldo, and J.P. Di Marco Rate control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE study group) N Engl J Med 347 2002 1834 1840
39. J. Carlsson, S. Miketic, and J. Windeler STAF (Strategies of Treatment of Atrial Fibrillation) J Am Coll Cardiol 41 2003 1690 1696
40. The AFFIRM investigators Baseline characteristics of patients with atrial fibrillation: the AFFIRM study Am Heart H 143 2002 991 1001
41. D.G. Wyse, A. Waldo, and J.P. Di Marco The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) investigators: a comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
42. Opolski G., Torbicki A., Kosior D., et al. HOT CAFÉ Trial. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish how to treat chronic atrial fibrillation (HOT CAFE) study Chest 2004;126:476-86.
43. Roy Denis, Talajic Mario, and Nattel Stanley Rhythm control versus rate control for atrial fibrillation and heart failure New Engl J Med 358 2008 2667 2677
44. S.D. Corley, A.E. Epstein, and J.P. DiMarco Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study Circulation 109 2004 1509 1513
45. D.G. Sherman, S.G. Kim, and B.S. Boop Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study Arch Intern Med 165 2005 1185 1191
46. V. Fuster, L. Rydén, and D. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration With the European Heart Rhythm Association and the Heart Rhythm Society JACC 48 2006 e149 e246
47. D.E. Singer, G.W. Albers, and J.E. Dalen Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 429S 456S
48. K. Wachtell, M. Lehto, and E. Gerdts Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study J Am Coll Cardiol 45 2005 712 719
49. E. Vermes, J.C. Tardif, and M. Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfuntion (SOLVD) trials Circulation 107 2003 2926 2931
50. O. Pedersen, H. Bagger, L. Kober, and C. Torp-Pedersen Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376 380
51. A.H. Madrid, M. Bueno, and J. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study Circulation 106 2002 331 336
52. N. Dagres, G. Karatasakis, and F. Panou Pre-treatment with irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation Eur Heart J 27 2006 2062 2068
53. I. Moreno, R. Caballero, and T. González Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization J Pharmacol Exp Ther 304 2003 862 873
54. The GISSI AF Investigators Valsartan for prevention of recurrent atrial fibrillation N Engl J Med 360 2009 1606 1617
55. J.G. Cleland, A.P. Coletta, A. Yassin, L. Buga, A. Torabi, and A.L. Clark Clinical trials update from the European Society Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT Survey, German pre-SCD II registry and MADIT-CRT Eur J Heart Fail 11 2009 1214 1219
56. F.G. Cosio, E. Aliot, and G.L. Botto Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences; reasons for change to active antiarrhythmic treatment at the time of the first detected episode Europace 10 2008 21 27
57. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150